Professional
Added to YB: 2026-01-26
Pitch date: 2026-01-22
FNCH [neutral]
Finch Therapeutics Group, Inc.
-8.13%
current return
Author Info
No bio for this author
Company Info
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Market Cap
$22.8M
Pitch Price
$14.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.95
P/E
-1.61
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Arquitos Capital Management Portfolio Holding: Finch Therapeutics Group, Inc.
FNCH (holding update): Won $30M jury award vs Ferring for patent infringement in Aug 2024, plus ongoing royalties & post-trial interest pending judge decision. Willful infringement finding opens door for 3x enhanced damages. Shares +19% in 2025 to $13.49 despite no case updates. Interest accrues at Fed rate +5%.
Read full article (1 min)